SCM
ANIP icon

Stevens Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Stevens Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,417
Closed -$207K – 837
2017
Q2 		$207K Buy
+4,417
New +$213K 0.01% 764

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Stevens Capital Management's ANIP Position: Q3 2017 in Review

Stevens Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 4,417 shares — an estimated $207K sold.

Stevens Capital Management first reported a position in ANIP in Q2 2017 and held it in 1 quarter. The position peaked at $207K in Q2 2017. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

  • Stevens Capital Management reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Stevens Capital Management sold 4,417 ANI Pharmaceuticals shares in Q3 2017, an estimated $207K.
  • Stevens Capital Management first reported a position in ANI Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Stevens Capital Management's ANI Pharmaceuticals position peaked at $207K in Q2 2017.
  • 146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Stevens Capital Management's 13F filing for Q3 2017, filed 1 Nov 2017.